Should You Buy Arrowhead Pharmaceuticals Inc (ARWR) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BUY now for a long-term (beginner) investor. ARWR’s trend structure is bullish (stacked moving averages) and Wall Street has recently repriced targets sharply higher on obesity/siRNA data and a catalyst-heavy roadmap. Options positioning is strongly call-skewed (bullish sentiment). Despite some short-term momentum not being fully “clean” (MACD still slightly negative), the current pre-market level (~67.87) is close to the key pivot (66.43) and offers a reasonable entry without waiting for a perfect pullback.
Technical Analysis
Price/Trend: Pre-market ~67.87 (+1.43%), trading just above the pivot (66.43). Trend is constructive with bullish moving average alignment (SMA_5 > SMA_20 > SMA_200), which supports a long-term uptrend bias.
Momentum: RSI(6) ~51 (neutral), implying no immediate overbought/oversold condition. MACD histogram -0.374 (below zero) but negatively contracting, suggesting downside momentum is fading and a turn higher is plausible if price pushes through near resistance.
Levels: Support S1 ~62.80 (then S2 ~60.55). Resistance R1 ~70.06 (then R2 ~72.31). A break/hold above ~70 would reinforce continuation.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent trend: Clear positive shift with multiple large price-target raises in January 2026 while maintaining mostly Buy/Overweight stances; even neutrals lifted targets materially.
- B. Riley: PT to $101 from $61 (Buy)
- H.C. Wainwright: PT to $100 from $85 (Buy)
- Piper Sandler: PT to $100 from $70 (Overweight) (earlier Dec)
- Chardan: PT to $80 from $60 (Buy)
- Morgan Stanley: PT to $81 from $48 (Equal Weight)
- Goldman Sachs: PT to $85 from $50 (Neutral)
Wall Street pros: Obesity RNAi data viewed as validating, potentially additive with GLP-1s; expanded long-term platform value; multiple upcoming catalysts.
Wall Street cons: Some firms remain Neutral/Market Perform (e.g., Goldman Neutral; Bernstein Market Perform), reflecting that the obesity story is early and the stock remains catalyst- and data-dependent.
Politicians/Congress: No recent congress trading data available in the last 90 days. Influential-figure activity: none provided. Insiders: neutral trend reported.
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 75.5 USD with a low forecast of 35 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 75.5 USD with a low forecast of 35 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 65.580
Current: 65.580
